{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:13:14Z","timestamp":1784297594342,"version":"3.55.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Johns Hopkins Thyroid Tumor Center"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Radioactive\u00a0iodine (RAI) is safe and effective in most patients with hyperthyroidism but not all individuals are cured by the first dose, and most develop post-RAI hypothyroidism.\u00a0Postoperative\u00a0RAI therapy for remnant\u00a0ablation\u00a0is\u00a0successful in\u00a080\u201390% of thyroid cancer patients and\u00a0sometimes induces remission of nonresectable cervical and\/or distant metastatic disease but the\u00a0effective tumor dose is usually not precisely known and must be moderated to avoid short- and long-term adverse effects on other tissues. The Collar Therapy Indicator (COTI) is a radiation detection device embedded in a cloth collar secured around the patient\u2019s neck and connected to a recording and data transmission box. In previously published experience, the data can be collected at multiple time points, reflecting local cervical RAI exposure and correlating well with conventional methods. We evaluated the real-time uptake of RAI in patients with hyperthyroid Graves\u2019 disease and thyroid cancer. We performed a pilot feasibility prospective study. Data were analyzed using R<jats:sup>\u00a9<\/jats:sup> (version 4.0.3, The R Foundation for Statistical Computing, 2020), and Python (version 3.6, Matplotlib version 3.0.3). The COTI was able to provide a quantitative temporal\u00a0pattern of uptake within the thyroid in persons with Graves\u2019 disease and lateralized the remnant tissue in persons with thyroid cancer. The study has\u00a0demonstrated that the portable collar radiation detection device outside of a healthcare facility is accurate and feasible for use after administration of RAI for diagnostic studies and therapy to provide a complete collection of fractional target radioactivity data compared to that traditionally acquired with clinic-based measurements at one or two time-points.<\/jats:p><jats:p><jats:italic>Clinical Trials Registration<\/jats:italic> NCT03517579, DOR 5\/7\/2018.<\/jats:p>","DOI":"10.1038\/s41598-021-97408-y","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T10:02:41Z","timestamp":1631786561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-time quantitation of thyroidal radioiodine uptake in thyroid disease with monitoring by a collar detection device"],"prefix":"10.1038","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03517579","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Prasanna","family":"Santhanam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmay","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Roussin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Frey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sgouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Ladenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"97408_CR1","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross, D. S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343\u20131421. https:\/\/doi.org\/10.1089\/thy.2016.0229 (2016).","journal-title":"Thyroid"},{"key":"97408_CR2","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2013-1954","volume":"98","author":"V Sundaresh","year":"2013","unstructured":"Sundaresh, V. et al. Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: A systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 98, 3671\u20133677. https:\/\/doi.org\/10.1210\/jc.2013-1954 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"97408_CR3","volume-title":"Nuclear Medicine: The Requisites e-Book","author":"HA Ziessman","year":"2013","unstructured":"Ziessman, H. A. & O\u2019Malley, J. P. Nuclear Medicine: The Requisites e-Book (Elsevier Health Sciences, 2013)."},{"key":"97408_CR4","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00259-016-3595-y","volume":"44","author":"P Brinks","year":"2017","unstructured":"Brinks, P. et al. Measuring the actual I-131 thyroid uptake curve with a collar detector system: a feasibility study. Eur. J. Nucl. Med. Mol. Imaging 44, 935\u2013940. https:\/\/doi.org\/10.1007\/s00259-016-3595-y (2017).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"97408_CR5","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s00411-020-00849-8","volume":"59","author":"M Abuqbeitah","year":"2020","unstructured":"Abuqbeitah, M., Demir, M., Yeyin, N., Sager, S. & Gray, D. Thyroid uptake test with portable device (COTI) after (131)I tracer administration: Proof of concept. Radiat. Environ. Biophys. 59, 553\u2013558. https:\/\/doi.org\/10.1007\/s00411-020-00849-8 (2020).","journal-title":"Radiat. Environ. Biophys."},{"key":"97408_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen, B. R. et al. 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid Off. J. Am. Thyroid Assoc. 26, 1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020 (2016).","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"97408_CR7","first-page":"66","volume-title":"Nuclear Medicine: The Requisites e-Book","author":"HA Ziessman","year":"2013","unstructured":"Ziessman, H. A. & O\u2019Malley, J. P. Nuclear Medicine: The Requisites e-Book 4th edn, 66\u201398 (Elsevier Health Sciences, 2013).","edition":"4"},{"key":"97408_CR8","unstructured":"Ziessman, H. A., O'Malley, J. P., Thrall, J. H. & Fahey, F. H. Nuclear Medicine: The Requisites (Requisites in Radiology), 4th edn. 66\u201398 (2013)."},{"key":"97408_CR9","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/RLU.0b013e3182817c78","volume":"38","author":"JA de Jong","year":"2013","unstructured":"de Jong, J. A., Verkooijen, H. M., Valk, G. D., Zelissen, P. M. & de Keizer, B. High failure rates after (131)I therapy in Graves hyperthyroidism patients with large thyroid volumes, high iodine uptake, and high iodine turnover. Clin. Nucl. Med. 38, 401\u2013406. https:\/\/doi.org\/10.1097\/RLU.0b013e3182817c78 (2013).","journal-title":"Clin. Nucl. Med."},{"key":"97408_CR10","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1118\/1.3093237","volume":"36","author":"AC Traino","year":"2009","unstructured":"Traino, A. C. & Xhafa, B. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves\u2019 disease. Med. Phys. 36, 1212\u20131218. https:\/\/doi.org\/10.1118\/1.3093237 (2009).","journal-title":"Med. Phys."},{"key":"97408_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1507\/endocrj.ej11-0279","volume":"59","author":"Y Osaki","year":"2012","unstructured":"Osaki, Y., Sakurai, K., Arihara, Z., Hata, M. & Fukazawa, H. Prediction of late (24-hour) radioactive iodine uptake using early (3-hour) uptake values in Japanese patients with Graves\u2019 disease. Endocr. J. 59, 173\u2013177. https:\/\/doi.org\/10.1507\/endocrj.ej11-0279 (2012).","journal-title":"Endocr. J."},{"key":"97408_CR12","first-page":"1055","volume":"30","author":"M Watanabe","year":"1993","unstructured":"Watanabe, M. et al. Estimation of effective half life of 131I in radioiodine therapy for Graves\u2019 disease using a single radioiodine uptake measurement. Kaku igaku 30, 1055\u20131062 (1993).","journal-title":"Kaku igaku"},{"key":"97408_CR13","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/RLU.0b013e31824851d1","volume":"37","author":"A Moura-Neto","year":"2012","unstructured":"Moura-Neto, A. et al. Predictive factors of failure in a fixed 15 mCi 131I-iodide therapy for Graves\u2019 disease. Clin. Nucl. Med. 37, 550\u2013554. https:\/\/doi.org\/10.1097\/RLU.0b013e31824851d1 (2012).","journal-title":"Clin. Nucl. Med."},{"key":"97408_CR14","doi-asserted-by":"publisher","first-page":"764","DOI":"10.3275\/8949","volume":"36","author":"FW Gibb","year":"2013","unstructured":"Gibb, F. W., Zammitt, N. N., Beckett, G. J. & Strachan, M. W. Predictors of treatment failure, incipient hypothyroidism, and weight gain following radioiodine therapy for Graves\u2019 thyrotoxicosis. J. Endocrinol. Invest. 36, 764\u2013769. https:\/\/doi.org\/10.3275\/8949 (2013).","journal-title":"J. Endocrinol. Invest."},{"key":"97408_CR15","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa1108586","volume":"366","author":"M Schlumberger","year":"2012","unstructured":"Schlumberger, M. et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N. Engl. J. Med. 366, 1663\u20131673. https:\/\/doi.org\/10.1056\/NEJMoa1108586 (2012).","journal-title":"N. Engl. J. Med."},{"key":"97408_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1210\/jc.2015-3695","volume":"101","author":"PW Ladenson","year":"2016","unstructured":"Ladenson, P. W. Precision medicine comes to thyroidology. J. Clin. Endocrinol. Metab. 101, 799\u2013803. https:\/\/doi.org\/10.1210\/jc.2015-3695 (2016).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97408-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97408-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97408-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T15:25:51Z","timestamp":1670081151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-97408-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["97408"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-97408-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"18 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PS, LS, TN, EF, GS and PWL have nothing to declare. JPS and DG are employed by AG Medical, the maker of the device. However, they had no role in the research protocol formulation, gathering and analysis of data or manuscript preparation. They provided the technical details of the device during the analysis. It has been elaborated in the beginning.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18479"}}